文献速递淋巴瘤

钙调磷酸酶抑制剂靶向慢性NFAT激活治疗弥漫性大B细胞淋巴瘤

Targeting chronic NFAT activation with calcineurin inhibitors in diffuse large B-cell lymphoma.
PubMed 文献 · Blood · 2020-01-01

研究显示,在弥漫性大B细胞淋巴瘤(DLBCL)两种分子亚型中,转录因子NFAT活性均慢性升高,且不依赖B细胞受体信号,而由钙流增加及钙调磷酸酶介导的NFAT去磷酸化所致;长期使用环孢素A或FK506可特异性杀伤活化B细胞样(ABC)DLBCL细胞,并与BCL-2、MCL-1抑制剂协同。

要点

  • NFAT在GCB与ABC两型DLBCL中均慢性激活,但不依赖B细胞受体信号。
  • 环孢素A或FK506长期抑制钙调磷酸酶,特异性杀伤ABC DLBCL细胞。
  • 钙调磷酸酶抑制剂与BCL-2、MCL-1抑制剂联合具有协同杀瘤作用。

核心结论

  • 慢性NFAT信号是ABC DLBCL的关键功能驱动因素,钙调磷酸酶抑制为治疗该侵袭性亚型提供了新策略。

研究设计与样本

  • 研究为体外细胞实验,纳入DLBCL两种主要分子亚型:生发中心B细胞样与活化B细胞样(ABC)DLBCL,未报告样本量。

主要发现

  • NFAT活性在两种DLBCL亚型中均慢性升高,其激活不依赖B细胞受体信号,而由钙流增加及钙调磷酸酶介导的NFAT去磷酸化所介导。
  • 环孢素A或FK506长期抑制钙调磷酸酶,可特异性引起ABC DLBCL细胞强效细胞毒作用。
  • 钙调磷酸酶抑制剂的抗肿瘤效应与c-Jun、白细胞介素-6和白细胞介素-10表达降低相关,这些基因为NFAT靶基因,对ABC DLBCL存活尤为重要。
  • 钙调磷酸酶阻断与BCL-2及MCL-1抑制剂在杀伤ABC DLBCL细胞中具有协同作用。

临床怎么用

  • 对ABC DLBCL可考虑评估钙调磷酸酶抑制剂(环孢素A、FK506)的抗肿瘤作用,并探索与BCL-2、MCL-1抑制剂的联合策略。

局限性

  • 研究为体外实验,尚未报告临床前动物模型或临床试验数据,钙调磷酸酶抑制剂在DLBCL患者中的疗效与安全性有待验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diffuse large B-cell lymphoma (DLBCL) represents the most common adult lymphoma and can be divided into 2 major molecular subtypes: the germinal center B-cell-like and the aggressive activated B-cell-like (ABC) DLBCL. Previous studies suggested that chronic B-cell receptor signaling and increased NF-κB activation contribute to ABC DLBCL survival. Here we show that the activity of the transcription factor NFAT is chronically elevated in both DLBCL subtypes. Surprisingly, NFAT activation is independent of B-cell receptor signaling, but mediated by an increased calcium flux and calcineurin-mediated dephosphorylation of NFAT. Intriguingly, although NFAT is activated in both DLBCL subtypes, long-term calcineurin inhibition with cyclosporin A or FK506, both clinically approved drugs, triggers potent cytotoxicity specifically in ABC DLBCL cells. The antitumor effects of calcineurin inhibitors are associated with the reduced expression of c-Jun, interleukin-6, and interleukin-10, which were identified as NFAT target genes that are particularly important for the survival of ABC DLBCL. Furthermore, calcineurin blockade synergized with BCL-2 and MCL-1 inhibitors in killing ABC DLBCL cells. Collectively, these findings identify constitutive NFAT signaling as a crucial functional driver of ABC DLBCL and highlight calcineurin inhibition as a novel strategy for the treatment of this aggressive lymphoma subtype.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Bucher P, Erdmann T, Grondona P, et al. Targeting chronic NFAT activation with calcineurin inhibitors in diffuse large B-cell lymphoma. Blood. 2020. PMID: 31794606. doi:10.1182/blood.2019001866

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。